Objectives: Hepatitis C Virus (HCV) is a significant cause of chronic liver disease. Among at-risk populations, access to diagnosis and treatment is challenging. We describe an integrated model of care, Hepcare Europe, developed to address this challenge. Methods: Using a case-study approach, we describe the cascade of care outcomes at all sites. Cost analyses estimated the cost per person screened and linked to care. Results: A total of 2608 participants were recruited across 218 clinical sites. HCV antibody test results were obtained for 2568(985%); 1074(418%) were antibody-positive, 687(605%) tested positive for HCV-RNA, 650(605%) were linked to care, and 319(435%) started treatment. 196(614%) of treatment initiates achieved a Sustained Viral Response (SVR) at dataset closure, 108(339%) were still on treatment, eight (27%) defaulted from treatment, and seven (26%) had virologic failure or died. The cost per person screened varied from s194 to s635, while the cost per person linked to care varied from s364 to s2035. Conclusions: Hepcare enhanced access to HCV treatment and cure, and costs were affordable in all settings, offering a framework for scale-up and reproducibility.